Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,313,254
  • Shares Outstanding, K 116,173
  • Annual Sales, $ 306,490 K
  • Annual Income, $ 94,180 K
  • 60-Month Beta 1.04
  • Price/Sales 9.87
  • Price/Cash Flow 33.76
  • Price/Book 6.66
Trade CORT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.17
  • Number of Estimates 3
  • High Estimate 0.19
  • Low Estimate 0.15
  • Prior Year 0.24
  • Growth Rate Est. (year over year) -29.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.50 +11.84%
on 12/30/20
29.28 -2.60%
on 01/19/21
+1.33 (+4.89%)
since 12/24/20
3-Month
16.52 +72.64%
on 10/30/20
29.28 -2.60%
on 01/19/21
+10.67 (+59.78%)
since 10/26/20
52-Week
9.70 +194.02%
on 03/23/20
29.28 -2.60%
on 01/19/21
+15.47 (+118.46%)
since 01/24/20

Most Recent Stories

More News
Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

PFE : 37.31 (+0.08%)
MRK : 80.25 (-1.11%)
BMY : 64.44 (-0.60%)
CORT : 28.52 (-0.14%)
Why Is Corcept (CORT) Up 25.8% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CORT : 28.52 (-0.14%)
Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

MRK : 80.25 (-1.11%)
CORT : 28.52 (-0.14%)
L Brands, Sonos rise; United Airlines, Cubic fall

NEW YORK (AP) — Stocks that moved heavily or traded substantially Thursday:

UAL : 41.25 (+2.15%)
SONO : 27.24 (-1.27%)
JACK : 100.39 (-0.66%)
NUAN : 47.79 (-1.08%)
CUB : 66.78 (-0.03%)
CORT : 28.52 (-0.14%)
Thinking about buying stock in Aptevo Therapeutics, Electrameccanica Vehicles, AstraZeneca, Corcept Therapeutics, or 22nd Century Group?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APVO, SOLO, AZN, CORT, and XXII.

XXII : 2.69 (-4.27%)
APVO : 36.57 (+5.36%)
AZN : 54.44 (+0.80%)
SOLO : 8.63 (+5.89%)
CORT : 28.52 (-0.14%)
U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept's U.S. Patent No.10,195,214

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 28.52 (-0.14%)
New Strong Sell Stocks for November 5th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

CORT : 28.52 (-0.14%)
ASC : 3.42 (+4.27%)
BWEN : 11.55 (+3.31%)
ALX : 275.42 (-1.51%)
EIDX : 122.21 (-4.85%)
Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View

Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year. Shares fall in after-hours trading.

ENDP : 7.32 (+0.55%)
MRK : 80.25 (-1.11%)
BMY : 64.44 (-0.60%)
CORT : 28.52 (-0.14%)
Corcept Therapeutics (CORT) Lags Q3 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

CORT : 28.52 (-0.14%)
Corcept: 3Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported third-quarter earnings of $21.6 million.

CORT : 28.52 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

3rd Resistance Point 29.74
2nd Resistance Point 29.35
1st Resistance Point 28.93
Last Price 28.52
1st Support Level 28.12
2nd Support Level 27.73
3rd Support Level 27.31

See More

52-Week High 29.28
Last Price 28.52
Fibonacci 61.8% 21.80
Fibonacci 50% 19.49
Fibonacci 38.2% 17.18
52-Week Low 9.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar